Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 49, Issue 1, pp 136–137 | Cite as

Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al.

  • Antonella MameliEmail author
  • Paola Schirru
  • Mariagrazia Porru
  • Francesco Marongiu
  • Doris Barcellona
Letter to the Editor
  • 28 Downloads

To the Editor,

We read with great interest the recent paper by Wojszel et al. published recently in Journal of Thrombosis and Thrombolysis [1]. In the article, the authors suggested that Oral anticoagulant (OACs) are often underused in elderly patients with atrial fibrillation (AF) because frailty status and anemia diagnosis. We have showed similar results in our patients and we would like to make some comments. We performed an analysis in 250 consecutive geriatric patients (123 males and 127 females; median age 78.9 years) with AF admitted to an acute internal Unit of an hospital in Cagliari, coming from the Emergency Department to evaluate trends in OACs use in real world. We examine the possibility of prescribing the direct oral anticoagulants (DOACs) and their actual prescription at discharge. Our data showed that at admission the patients with anticoagulant therapy (ACs) were 158 (9 with Heparin, 44 with DOACs, 105 with Vitamin K antagonist (AVK)). At discharge the number of...

Notes

Compliance with ethical standards

Conflict of interest

The authors have no financial or other conflicts of interest

References

  1. 1.
    Wojszel ZB, Kasiukiewicz A (2019) Determinants of anticoagulant therapy in atrial fibrillation at discharge from a geriatric ward: cross sectional study. J Thromb Thrombolysis.  https://doi.org/10.1007/s11239-019-01937-3 CrossRefPubMedGoogle Scholar
  2. 2.
    Marzec LN, Goscch KL, Chan PS et al (2015) Abstract 14902: the introduction of novel oral anticoagulants has improved overall oral anticoagulants rates in atrial fibrillation: insights from the NCDR PINNACLE Registry. CirculationGoogle Scholar
  3. 3.
    Cyr L, Francis K (1992) Measures of clinical agreement for nominal and categorical data: the kappa coefficient. Comput Biol Med 22:239CrossRefGoogle Scholar
  4. 4.
    Brais C, Larochelle J, Turgeon MH, Blais L, Farand P (2017) Predictors of direct oral anticoagulants utilization for thromboembolism prevention in atrial fibrillation. J Pharm Sci 20:8–14Google Scholar
  5. 5.
    AbuDagga A, Stephenson J, Fu A-C, Kwong WJ, Tan H, Weintraub WS (2014) Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res 14:310CrossRefGoogle Scholar
  6. 6.
    Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, Spettell CM, Brennan TA, Matlin OS, Avorn J, Choudhry NK (2014) Patterns of initiation of oral anticoagulants in patients with atrial fibrillation: quality and cost implications. Am J Med 127:1075–1082CrossRefGoogle Scholar
  7. 7.
    Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al (2018) The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393CrossRefGoogle Scholar
  8. 8.
    Desmaele S, Steurbaut S, Cornu P, Brouns R, Dupont AG (2016) Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients? Eur J Clin Pharmacol 72:1125–1134CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Haemostasis and Thrombosis Unit, AOU “Duilio Casula”University of CagliariCagliariItaly
  2. 2.Internal Medicine and Haemocoagulopathies Unit, AOU “Duilio Casula”University of CagliariCagliariItaly
  3. 3.Azienda Ospedaliero UniversitariaMonserratoItaly

Personalised recommendations